正中目标：新型 RAS-GTP 抑制剂。

IF 72.5 1区医学 Q1 ONCOLOGY

Nature Reviews Cancer Pub Date : 2024-05-10 DOI:10.1038/s41568-024-00703-9

Daniela Senft

引用次数: 0

摘要

同时发表在《自然》杂志上的两项研究报告了 RMC-7977 的开发和临床前活性，RMC-7977 是一种多选择性抑制剂，靶向 RAS 的活性 GTP 结合形式。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Right ON target: a new RAS-GTP inhibitor

查看原文本刊更多论文

Right ON target: a new RAS-GTP inhibitor

Two studies published concurrently in Nature report the development and preclinical activity of RMC-7977, a multi-selective inhibitor targeting the active, GTP-bound form of RAS.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Cancer 医学-肿瘤学

CiteScore

111.90

自引率

0.40%

发文量

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Cancer, a part of the Nature Reviews portfolio of journals, aims to be the premier source of reviews and commentaries for the scientific communities it serves. The correct abbreviation for abstracting and indexing purposes is Nat. Rev. Cancer. The international standard serial numbers (ISSN) for Nature Reviews Cancer are 1474-175X (print) and 1474-1768 (online). Unlike other journals, Nature Reviews Cancer does not have an external editorial board. Instead, all editorial decisions are made by a team of full-time professional editors who are PhD-level scientists. The journal publishes Research Highlights, Comments, Reviews, and Perspectives relevant to cancer researchers, ensuring that the articles reach the widest possible audience due to their broad scope.